Mutations in the BTK and PLCG2 genes have the potential to be used as a biomarker for relapse of chronic lymphocytic leukemia (CLL) after treatment with ibrutinib, according to a retrospective review published in the...
Mutations in the BTK and PLCG2 genes have the potential to be used as a biomarker for relapse of chronic lymphocytic leukemia (CLL) after treatment with ibrutinib, according to a retrospective review published in the...
...